Weekly Research Analysts’ Ratings Updates for Ventas (VTR)

Several analysts have recently updated their ratings and price targets for Ventas (NYSE: VTR):

  • 9/1/2026 – Ventas had its price target raised by Wells Fargo & Company from $96.00 to $104.00. They now have an “overweight” rating on the stock.
  • 8/31/2026 – Ventas had its price target raised by Barclays PLC from $99.00 to $102.00. They now have an “equal weight” rating on the stock.
  • 8/14/2026 – Ventas had its price target raised by Royal Bank Of Canada from $98.00 to $99.00. They now have an “outperform” rating on the stock.
  • 8/11/2026 – Ventas had its price target raised by BMO Capital Markets from $105.00 to $107.00. They now have an “outperform” rating on the stock.
  • 8/4/2026 – Ventas had its price target raised by Citigroup Inc. from $100.00 to $110.00. They now have a “buy” rating on the stock.
  • 7/31/2026 – Ventas had its price target raised by Cantor Fitzgerald from $97.00 to $102.00. They now have an “overweight” rating on the stock.
  • 7/22/2026 – Ventas had its price target raised by Mizuho from $98.00 to $104.00. They now have an “outperform” rating on the stock.
  • 7/21/2026 – Ventas was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
  • 7/8/2026 – Ventas was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
  • 7/7/2026 – Ventas is now covered by Barclays PLC. They set an “equal weight” rating and a $99.00 price target on the stock.

Insider Activity

In related news, Director Michael J. Embler acquired 2,500 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $78.81 per share, for a total transaction of $197,025.00. Following the transaction, the director owned 19,202 shares of the company’s stock, valued at approximately $1,513,309.62. The trade was a 14.97% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.53% of the company’s stock.

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.

See Also

Receive News & Ratings for Ventas Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas Inc and related companies with MarketBeat.com's FREE daily email newsletter.